For example, RA patients who are under high dose of immunesuppressants at time of COVID-19 hospitalization would have a higher risk than benefit if administered IL-6, JAK or IL-1 inhibitor as this drugs will increase the possibility of serious hospital-acquired infections [91]. This evidence concerns the gene IL6 and COVID-19.